At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, intermediate risk, low risk, Provenge, ProVent, sipuleucel-T, surveillance, trial | Leave a comment »
So one of the more interesting things to be announced since your sitemaster arrived at the annual meeting of the American Urological Association (AUA) in San Francisco yesterday was this one: … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, Dendreon, Provenge, sipuleucel-T, surveillance, trial | 1 Comment »
It wouldn’t be wise to expect anything big in a hurry, but it is now clear that the Sanpower Group, which acquired Dendreon about a year ago, has serious plans to do things that the “old Dendreon” never did to optimize the potential of sipuleucel-T (Provenge). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: access, availability, Provenge, sipuleucel-T | 2 Comments »
At the end of last week, Dendreon finally became a self-standing, wholly owned subsidiary of the Chinese company known as the Sanpower Group. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Dendreon, Provenge, sipuleucel-T | 1 Comment »
In general, being of African American race is not a good thing when it comes to prostate cancer-related risk (for getting diagnosed with the disease or for outcomes over time). However, … … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: African American, Provenge, sipuleucel-T, Treatment | Leave a comment »
According to a media release issued rather quietly a week ago, a large Chinese conglomerate has now bought Provenge (sipuleucel-T) from Valeant, which had acquired it when Valeant bought Dendreon. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: Provenge, sipuleucel-T | 3 Comments »
The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: guidelines, immunotherapy, Prostvac, Provenge, sipuleucel-T | 3 Comments »
A new review article has provided a detailed update on the current state of knowledge about the use of sipuleucel-T (Provenge®) in the treatment of advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: Provenge, review, sipuleucel-T, update | Leave a comment »
After approval by a bankruptcy court judge on Friday, the final acquisition of Dendreon by Valeant Pharmaceuticals is expected to be completed today, ensuring that sipuleucel-T (Provenge) will remain available to prostate cancer patients. Whether Valeant will actually invest in the further development of sipuleucel-T is unknown at this time.
Filed under: Uncategorized | Tagged: Dendreon, Provenge, sipuleucel-T, Valeant | Leave a comment »
According to information on the Reuters web site, Valeant, of Laval, Quebec, is to acquire Seattle-based Dendreon’s sipuleucel-T (Provenge) and other assets for $400 million in cash. Apparently there were no other qualified bidders that sought to compete with Valeant for these assets. Court approval of the sale will be sought on February 20.
Filed under: Uncategorized | Tagged: Dendreon, Provenge, sipuleucel-T | Leave a comment »
According to a report on FirstWord Pharma some time yesterday, there are at least two — and maybe more — potential bidders for the assets of Dendreon. The good news for patients is therefore that sipuleucel-T (Provenge) will almost certainly continue to be available for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Management, Treatment | Tagged: Dendreon, Provenge, sipuleucel-T | 3 Comments »
According to a report on the PharmaFile web site, the National Institute for Health and Care Excellence (NICE) in England has rejected Dendreon’s application for coverage of the costs of treatment with sipuleucel-T (Provenge) for the second time in less than a year. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: England, NICE, Provenge, sipuleucel-T | 3 Comments »
According to a media release issued by Dendreon Corp. early this morning, the company will be declaring Chapter 11 bankruptcy but is assuring physicians and patients that sipuleucel-T (Provenge) will continue to remain available during the company’s restructuring. What is a good deal less clear is whether the company will be sold after the restructuring or will continue to operate as a stand-alone entity.
Filed under: Uncategorized | Tagged: Provenge, sipuleucel-T | Leave a comment »
The National Institute for Health and Clinical Excellence (NICE) in the UK has issued a statement that, according to preliminary draft guidelines, it has rejected the use of sipuleucel-T (Provenge) to treat patients with metastatic prostate cancer before they have received chemotherapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cost, England, NICE, Provenge, sipuleucel-T, value | 3 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 